峆一药业
(430478)
| 流通市值：7.58亿 | | | 总市值：12.45亿 |
| 流通股本：3423.35万 | | | 总股本：5622.05万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 196,755,675.33 | 137,409,942.22 | 70,024,905.48 | 226,253,170.32 |
| 营业收入 | 196,755,675.33 | 137,409,942.22 | 70,024,905.48 | 226,253,170.32 |
| 二、营业总成本 | 159,583,009.37 | 107,412,546.17 | 56,990,296.85 | 190,044,319.88 |
| 营业成本 | 121,227,175.45 | 83,477,594.77 | 44,682,876.52 | 144,933,411.17 |
| 税金及附加 | 1,893,742.4 | 1,203,882.91 | 550,875.09 | 2,936,147.36 |
| 销售费用 | 1,331,995.81 | 1,122,606.61 | 570,707.64 | 2,000,242.15 |
| 管理费用 | 21,599,559.97 | 13,539,524.45 | 6,926,803.4 | 25,521,043.51 |
| 研发费用 | 15,384,389.34 | 9,691,309.95 | 4,870,939.79 | 15,818,099.64 |
| 财务费用 | -1,853,853.6 | -1,622,372.52 | -611,905.59 | -1,164,623.95 |
| 其中:利息费用 | 126,433.29 | 76,381.75 | - | 78,279.62 |
| 其中:利息收入 | 449,471.95 | 392,743.37 | - | 904,788.28 |
| 加:公允价值变动收益 | 602,001.38 | -132,915.3 | 687,046.58 | 519,583.56 |
| 加:投资收益 | 2,692,577.69 | 2,239,004.59 | 131,572.6 | 2,549,030.15 |
| 资产处置收益 | - | - | - | -75,225.1 |
| 资产减值损失(新) | - | - | - | -3,143,171.07 |
| 信用减值损失(新) | 186,874.8 | -236,161.66 | -401,857.49 | 116,579.51 |
| 其他收益 | 1,456,879.77 | 1,113,735.29 | 469,020.43 | 2,164,873.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 42,110,999.6 | 32,981,058.97 | 13,920,390.75 | 38,340,520.95 |
| 加:营业外收入 | 130,000 | 130,000 | - | 13,702,608 |
| 减:营业外支出 | 116,350.1 | 10,000 | 10,000 | 518,277.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 42,124,649.5 | 33,101,058.97 | 13,910,390.75 | 51,524,851.01 |
| 减:所得税费用 | 6,289,312.13 | 5,167,021.68 | 2,256,288.15 | 7,470,372.42 |
| 六、净利润 | 35,835,337.37 | 27,934,037.29 | 11,654,102.6 | 44,054,478.59 |
| 持续经营净利润 | 35,835,337.37 | 27,934,037.29 | 11,654,102.6 | 44,054,478.59 |
| 归属于母公司股东的净利润 | 37,401,751.95 | 29,125,262.12 | 12,455,923.58 | 48,572,460.01 |
| 少数股东损益 | -1,566,414.58 | -1,191,224.82 | -801,820.98 | -4,517,981.42 |
| (一)基本每股收益 | 0.67 | 0.52 | 0.31 | 1.27 |
| 九、综合收益总额 | 35,835,337.37 | 27,934,037.29 | 11,654,102.6 | 44,054,478.59 |
| 归属于母公司股东的综合收益总额 | 37,401,751.95 | 29,125,262.12 | 12,455,923.58 | 48,572,460.01 |
| 归属于少数股东的综合收益总额 | -1,566,414.58 | -1,191,224.82 | -801,820.98 | -4,517,981.42 |
| 公告日期 | 2024-10-28 | 2024-08-28 | 2024-04-26 | 2024-04-11 |
| 审计意见(境内) | | | | 标准无保留意见 |